Qutenza (capsaicin) / Astellas, Grunenthal, LTS Lohmann Therapy Systems, Apotex - LARVOL DELTA

SerCaBot: Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (clinicaltrials.gov) - P2 | N=123 | Recruiting | Sponsor: Centre Oscar Lambret | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2027 ➔ Dec 2027 | Initiation date: Feb 2025 ➔ Jun 2025 | Trial primary completion date: Feb 2027 ➔ Aug 2027

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Musculoskeletal Pain • Neuralgia • Pain

Evaluation of the Treatment Effect of Capsaicin (179mg) Patch on Chronic Regional Pain Syndrome (NeuPSIG 2025) - No abstract available

CNS Disorders • Musculoskeletal Pain • Pain

Progressive Response of Repeated Treatment with High-Concentration (179 mg) Capsaicin Patch in Peripheral Neuropathic Pain After Surgical or Traumatic Nerve Injury: Findings from the 12-Month German CASPAR Registry Study. (PubMed, Pain Ther) - "HCCP treatment is associated with reductions in pain intensity and improvements in sleep, mood, and overall QoL in patients with PNI. These benefits are amplified with continued treatment and are accompanied by reduced use of concomitant analgesics and more days of usual activities, although a direct causal relationship cannot be confirmed within the context of this observational study."

Journal • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain • Sleep Disorder

Progressive improvements in patient-reported outcomes with the high-concentration capsaicin patch: A retrospective cohort study in patients with painful diabetic peripheral neuropathy (CASPAR study). (PubMed, J Diabetes Complications) - "HCCP is a non-systemic treatment for pDPN associated with increasing improvements in neuropathic pain, sleep, mood, and QoL with successive treatments."

Journal • Retrospective data • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain

Case report: efficacy of capsaicin 8% (Qutenza) in the treatment of acute intercostal neuropathic pain post-removal of thoracic drainage tube (Euroanaesthesia 2025) - "After preparing the area with topical lidocaine 4%, the capsaicin patch was applied to the affected intercostal region. Although guidelines often recommend topical treatments as second-line options, recent studies have shown that capsaicin patches can outperform oral agents such as pregabalin in localized neuropathic pain (1). Emerging algorithms for treating localized neuropathic pain increasingly propose topical analgesics, including capsaicin patches, as first-line options, particularly for patients who cannot tolerate systemic therapies (2)."

Case report • Clinical • Musculoskeletal Diseases • Neuralgia • Orthopedics • Pain

High-Potency Capsaicin Patches (8%): A Promising Option for Dermatoses Associated With Neuropathic Pain and Pruritus. (PubMed, Int J Dermatol) - No abstract available

Journal • Dermatology • Neuralgia • Pain • Pruritus

Capsaicin Patch Therapy for Chronic Neuropathic Pain in Breast Cancer Survivors: Importance of Early Diagnosis and Intervention (ESTRO 2025) - "Capsaicin patch therapy demonstrates safety and efficacy in managing CNP, particularly when administered early. Administering the treatment prior to the initiation of radiotherapy in patients with neuropathic pain could potentially prevent chronicity and optimize outcomes. Early and accurate diagnosis is essential to align treatment with emerging guidelines for chronic pain management in breast cancer survivors."

Breast Cancer • Infectious Disease • Neuralgia • Oncology • Pain • Solid Tumor

Efficacy and safety of capsaicin 8% patches: The experience of a rheumatology department. (PubMed, SAGE Open Med) - "It seemed beneficial to repeat the application after the 1st one had failed. Burning sensations after placement were fairly frequent, usually moderate to high, but lasting only a short time."

Journal • Hematological Disorders • Immunology • Musculoskeletal Pain • Neuralgia • Osteoarthritis • Pain • Rheumatology

TEC-ORL: Study to Evaluate the Interest of Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain. (clinicaltrials.gov) - P2 | N=13 | Active, not recruiting | Sponsor: Institut Claudius Regaud | Recruiting ➔ Active, not recruiting | N=130 ➔ 13

Enrollment change • Enrollment closed • Head and Neck Cancer • Neuralgia • Oncology • Pain • Solid Tumor

Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. (PubMed, Lancet Neurol) - "Our results support a revision of the Neuropathic Pain Special Interest Group recommendations for the treatment of neuropathic pain. Treatment outcomes are modest and for some treatments uncertainty remains. Further large placebo-controlled or sham-controlled trials done over clinically relevant timeframes are needed."

Clinical • Journal • Retrospective data • Review • Addiction (Opioid and Alcohol) • Back Pain • Fibromyalgia • Lumbar Back Pain • Musculoskeletal Pain • Neuralgia • Novel Coronavirus Disease • Pain • Rheumatology

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: Averitas Pharma, Inc. | Trial completion date: Dec 2025 ➔ Mar 2027 | Initiation date: Aug 2024 ➔ Mar 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2026

Trial completion date • Trial initiation date • Trial primary completion date • Diabetic Neuropathy • Pain • Peripheral Neuropathic Pain

Clinical Manifestations of Neuropathic Pain and the Deleterious Effects of Chemotherapeutic Agents. (PubMed, Curr Drug Saf) - "A variety of chemotherapeutic agents can contribute to the development of CIPN, including vinca alkaloids, platinum-based antineoplastic agents, epothilones (ixabepilone), proteasome inhibitors (bortezomib), taxanes, and immunomodulatory drugs (thalidomide), along with the genetic factors...Pharmacological interventions, such as anticonvulsants, gabapentin, and pregabalin, are commonly used to manage neuropathic pain. Tricyclic antidepressants like amitriptyline and nortriptyline can be effective, but their use may be limited due to side effects...The lidocaine or capsaicin creams and patches can provide localized pain relief...Transcutaneous electrical nerve stimulation and spinal cord stimulation are invasive procedures that may be considered for severe, intractable pain. Complementary therapies and cognitive-behavioural therapy can help patients cope with pain and improve their quality of life."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Neuralgia • Oncology • Pain • Psychiatry • CEP72

CADOR: Capsaicin in Digital Osteoarthritis Versus Control (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: University Hospital, Clermont-Ferrand | Not yet recruiting ➔ Recruiting | Initiation date: Sep 2024 ➔ Mar 2025

Enrollment open • Trial initiation date • Immunology • Neuralgia • Osteoarthritis • Pain • Rheumatology

CADOR (Capsaicin in neuropathic-like pain in digital osteoarthritis) study protocol: a multicentre randomised parallel-group trial. (PubMed, BMJ Open) - P4 | "However, the effectiveness of an 8% capsaicin transdermal patch has never been tested in HOA patients with neuropathic-like pain in a randomised setting...Ethics approval was obtained from the French Health Authorities (Comité de protection des Personnes SUD EST V and Agence Nationale de Sécurité du Médicament) on 23 May 2024 in accordance with European Regulation n°536/2014 of 16 April 2014 (ref: 2024-511159-16-00) before participant enrolment. ClinicalTrials.gov: NCT06444919."

Clinical • Clinical protocol • Journal • CNS Disorders • Depression • Immunology • Mood Disorders • Musculoskeletal Pain • Neuralgia • Osteoarthritis • Pain • Psychiatry • Rheumatology

Algology in Oncology Osteopathic Support (ALGOS) (clinicaltrials.gov) - P=N/A | N=12 | Completed | Sponsor: Institut Toulousain d'Ostéopathie | Recruiting ➔ Completed | N=120 ➔ 12 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Enrollment change • Trial completion • Trial primary completion date • Breast Cancer • Neuralgia • Oncology • Pain • Solid Tumor

Apotex licenses exclusive Canadian rights to Qutenza from Grünenthal (Canada Newswire) - "Apotex Inc...announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain. Under the agreement, Searchlight Pharma...will pursue marketing authorization for Qutenza and market and distribute Qutenza in Canada upon regulatory approval. Grünenthal will receive an upfront payment in addition to regulatory milestone payments and royalties."

Licensing / partnership • Neuralgia • Pain

CAPSAPED: Analgesic Effectiveness of Capsaicin 8% Cutaneous Patch in Children (clinicaltrials.gov) - P3 | N=46 | Recruiting | Sponsor: University Hospital, Brest | Phase classification: P2 ➔ P3

Phase classification • Mood Disorders • Neuralgia • Pain

SerCaBot: Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (clinicaltrials.gov) - P2 | N=123 | Not yet recruiting | Sponsor: Centre Oscar Lambret

New P2 trial • Musculoskeletal Pain • Neuralgia • Pain

Narrative review of the efficacy and safety of the high-concentration (179mg) capsaicin patch in peripheral neuropathic pain with recommendations for clinical practice and future research. (PubMed, Pain Rep) - "In conclusion, the HC capsaicin patch is effective and well tolerated across a range of pNeP conditions, with increasing efficacy upon retreatment. It is a valuable treatment option, although more research is needed to refine its clinical use and explore its full therapeutic potential."

Journal • Review • Neuralgia • Pain • Peripheral Neuropathic Pain

Identifying Patient Subgroups in the Heterogeneous Chronic Pain Population Using Cluster Analysis. (PubMed, J Pain) - "Pain reduction following treatment was least in cluster 1 (28.6% after capsaicin patch, 18.2% after multidisciplinary treatment), compared to >50% for both treatments in clusters 2 and 3...One group with higher psychological burden showed poorer treatment outcomes. A web-based tool using this model could help clinicians tailor therapies by matching interventions to specific patient subgroups for improved outcomes."

Heterogeneity • Journal • CNS Disorders • Depression • Mood Disorders • Pain • Psychiatry

Evaluating Treatment Preferences and the Efficacy of Capsaicin 179 mg Patch vs. Pregabalin in a Randomized Trial for Postsurgical Neuropathic Pain in Breast Cancer: CAPTRANE. (PubMed, Cancers (Basel)) - " This comparative study in PSNP post breast cancer surgery, evaluating a single treatment of HCCP, shows a noninferior reduction in pain intensity, a superior reduction in painful area size, and a patient preference for HCCP compared with pregabalin. Despite limitations, it contributes valuable initial data for PSNP management in breast cancer care."

Journal • Breast Cancer • Neuralgia • Oncology • Pain • Solid Tumor

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

New P1 trial • Pain • Peripheral Neuropathic Pain

The Effect of Topical Capsaicin 8% on Pain in Chemotherapy-induced Peripheral Neuropathy. (PubMed, Pain Manag Nurs) - "Capsaicin 8% can have a beneficial analgesic effect in patients with CIPN-related pain but with a marked "on-off" effect. Mood changes were marginal. Quantitative sensory testing findings do not support earlier findings on nerve degeneration after capsaicin treatment, although the study size was small for definitive conclusions."

Journal • CNS Disorders • Depression • Mood Disorders • Pain • Peripheral Neuropathic Pain • Psychiatry

Overview of pain in Ukrainian war injured. (PubMed, Injury) - "The study of injuries caused in current armed conflicts can help us anticipate complications and understand and treat pain early to improve the independence of patients, especially of amputee patients."

Journal • Neuralgia • Pain

Assessing the efficacy of topical formulations in diabetic neuropathy: a narrative review. (PubMed, J Diabetes Metab Disord) - "Potential options include 8% Capsaicin patch, 5% Lidocaine patch, Clonidine gel, Topical gabapentin, and an amitriptyline and ketamine combination. A promising area of research that requires further study is the effect of a combination of topicals in alleviated DNP."

Journal • Review • Diabetic Neuropathy • Neuralgia • Pain